Literature DB >> 17981786

Fibroblast activation protein and chronic liver disease.

Xin Maggie Wang1, Tsun-Wen Yao, Naveed A Nadvi, Brenna Osborne, Geoffrey W McCaughan, Mark D Gorrell.   

Abstract

Fibroblast activation protein (FAP) is the member of Dipeptidyl Peptidase IV (DPIV) gene family that is most similar to DPIV. Four members of this family, DPIV, FAP, DP8 and DP9 possess a rare catalytic activity, hydrolysis of a prolyl bond two residues from the substrate N terminus. Crystal structures show that the soluble form of FAP comprises two domains, an alpha/beta-hydrolase domain and an 8-blade beta-propeller domain. The interface between these two domains forms the catalytic pocket, and an opening for substrate access to the internal active site. The FAP homodimer is structurally very similar to DPIV but FAP glycoprotein expression is largely confined to mesenchymal cells in diseased and damaged tissue, notably the tissue remodelling region in chronically injured liver. FAP peptide substrates include denatured collagen and alpha2-antiplasmin. The functional roles of FAP in tumors and fibrotic tissue are not fully understood. This review places FAP in the context of chronic liver injury pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17981786     DOI: 10.2741/2918

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  30 in total

1.  Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance.

Authors:  Min Shi; Dang-Hui Yu; Ying Chen; Chen-Yan Zhao; Jing Zhang; Qing-Hua Liu; Can-Rong Ni; Ming-Hua Zhu
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

2.  Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.

Authors:  Koen Jansen; Leen Heirbaut; Jonathan D Cheng; Jurgen Joossens; Oxana Ryabtsova; Paul Cos; Louis Maes; Anne-Marie Lambeir; Ingrid De Meester; Koen Augustyns; Pieter Van der Veken
Journal:  ACS Med Chem Lett       Date:  2013-03-18       Impact factor: 4.345

3.  Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Authors:  Liang-Chuan S Wang; Albert Lo; John Scholler; Jing Sun; Rajrupa S Majumdar; Veena Kapoor; Michael Antzis; Cody E Cotner; Laura A Johnson; Amy C Durham; Charalambos C Solomides; Carl H June; Ellen Puré; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2013-11-12       Impact factor: 11.151

4.  Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues.

Authors:  Véronique Dubois; Chris Van Ginneken; Hilde De Cock; Anne-Marie Lambeir; Pieter Van der Veken; Koen Augustyns; Xin Chen; Simon Scharpé; Ingrid De Meester
Journal:  J Histochem Cytochem       Date:  2009-02-02       Impact factor: 2.479

5.  Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.

Authors:  Sumaiya Chowdhury; Yiqian Chen; Tsun-Wen Yao; Katerina Ajami; Xin M Wang; Yury Popov; Detlef Schuppan; Patrick Bertolino; Geoffrey W McCaughan; Denise Mt Yu; Mark D Gorrell
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

6.  Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice.

Authors:  Angélica M Santos; Jason Jung; Nazneen Aziz; Joseph L Kissil; Ellen Puré
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

7.  Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.

Authors:  W Nathaniel Brennen; D Marc Rosen; Hao Wang; John T Isaacs; Samuel R Denmeade
Journal:  J Natl Cancer Inst       Date:  2012-08-21       Impact factor: 13.506

8.  Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations.

Authors:  M M Koczorowska; S Tholen; F Bucher; L Lutz; J N Kizhakkedathu; O De Wever; U F Wellner; M L Biniossek; A Stahl; S Lassmann; O Schilling
Journal:  Mol Oncol       Date:  2015-08-11       Impact factor: 6.603

9.  Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Tamyra D Downs; Patrick A McKee
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

Review 10.  Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?

Authors:  Ellen Puré; Albert Lo
Journal:  Cancer Immunol Res       Date:  2016-04       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.